Skye Bioscience Announces Phase 2a Trial Of SBI-100 OE In Glaucoma Patients Did Not Meet Primary Endpoint, Will Discontinue Related R&D And Focus On Metabolic Program; Phase 2 Obesity Trial For Nimacimab To Begin Dosing In Q3 2024
Portfolio Pulse from Benzinga Newsdesk
Skye Bioscience announced that its Phase 2a trial of SBI-100 OE in glaucoma patients did not meet the primary endpoint. As a result, the company will discontinue related R&D and shift focus to its metabolic program, with a Phase 2 obesity trial for Nimacimab set to begin dosing in Q3 2024.
June 10, 2024 | 12:21 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Skye Bioscience's Phase 2a trial for SBI-100 OE in glaucoma patients did not meet its primary endpoint. The company will discontinue related R&D and focus on its metabolic program, with a Phase 2 obesity trial for Nimacimab starting in Q3 2024.
The failure to meet the primary endpoint in the Phase 2a trial is a significant setback for Skye Bioscience, likely leading to a negative short-term impact on the stock price. However, the shift in focus to the metabolic program and the upcoming Phase 2 obesity trial for Nimacimab may provide some long-term optimism.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100